Ep 230 [14 October 2026]: Khaled El Emam, CEO & Founder at Woodway Assurance and Canada Research Chair in Medical AI at uOttawa – As a pioneer in health data de-identification and synthetic data, he recounted his career journey and explore how companies can protect privacy and prevent training data leakage in AI. Please check-out our website to join the club, get updates and see podcast recordings: https://rwd-rwe.club Disclaimer: The views expressed in this podcast are the guest's and host's alone, and do not reflect the official position of any organization or entity with whom they are, or have been, professionally affiliated.

Ep 229 [07 October 2026]: Dave Miller, CEO of Genesis Research Group – He recounted his career transitions spanning large pharma and advisory roles that helped shape his perspective on the use of RWD for evidence and the value that RWE provides companies of all sizes. Please check-out our website to join the club, get updates and see podcast recordings: https://rwd-rwe.club Disclaimer: The views expressed in this podcast are the guest's and host's alone, and do not reflect the official position of any organization or entity with whom they are, or have been, professionally affiliated.

Ep 228 [30 September 2026]: Jean-Paul "JP" Collet MD PhD, Chief Scientific Officer of Evidinno Outcomes Research – We discussed JP's unique background and discussed research that shifts from purely statistical significance to clinical signficance ... and even on to personally meangingful significance, that is, what outcome truly matters to each patient. Please check-out our website to join the club, get updates and see podcast recordings: https://rwd-rwe.club Disclaimer: The views expressed in this podcast are the guest's and host's alone, and do not reflect the official position of any organization or entity with whom they are, or have been, professionally affiliated.

Ep 222 [01 July 2026]: Katherine Byrne MS, Director of RWE and Innovative Evidence at Novartis – We discussed Katherine's unique background and discussed a truism today: that real-world evidence is powerful, but only if it resonates across industry and patients alike. How can we align data, language, and insights with what patients truly value in their care and health outcomes? Please check-out our website to join the club, get updates and see podcast recordings: https://rwd-rwe.club Disclaimer: The views expressed in this podcast are the guest's and host's alone, and do not reflect the official position of any organization or entity with whom they are, or have been, professionally affiliated.

Ep 223 [08 July 2026]: Schiffon Wong MPH, Founder and Principal of Schiffon Wong Strategic Advisory, where she advises biopharma executive leaders on evidence strategy for market access. She brings over 20 years of healthcare and life sciences experience, including nearly two decades inside pharma evidence functions — most notably as VP and Head of Neurology & Immunology, Global Value Demonstration at EMD Serono, with earlier roles at Bristol-Myers Squibb and Deloitte. She holds an MPH in Epidemiology from Columbia University and has authored approximately 100 publications and presentations. We discussed Schiffon's unique background and discussed that policy changes today are forcing a step-change in evidence rigor, Schiffon will focus on what that pressure exposes organizationally, and why research methodology is now table stakes, not the differentiator it was in the past. JCA — Joint Clinical Assessment, the EU-level HTA (Health Technology Assessment) process that took effect in 2025, requiring coordinated clinical evidence evaluation across member states before national reimbursement decisions. MFN — Most Favored Nation, a U.S. drug pricing policy concept requiring manufacturers to match the lowest price paid by comparable countries, with implications for how value must be demonstrated domestically. IRA — Inflation Reduction Act, the 2022 U.S. legislation that introduced Medicare drug price negotiation, among other provisions, fundamentally reshaping how manufacturers think about evidence requirements earlier in development. Please check-out our website to join the club, get updates and see podcast recordings: https://rwd-rwe.club Disclaimer: The views expressed in this podcast are the guest's and host's alone, and do not reflect the official position of any organization or entity with whom they are, or have been, professionally affiliated.

Ep 224 [22 July 2026]: Leon Rozenblit PhD, Founder, lecuturer and podcaster with a focus on healthcare AI, data strategy, and governance models – We discussed Leon's unique background and discussed that the hyphen between RWD and RWE is rarely considered but represents vast amounts of work and expertise: RWD does not automatically translate into RWE. In this episode, we will explore data refineries and their role in sourcing, aggregation, engineering, methodology, and the engineering to turn raw data into real-world evidence. Please check-out our website to join the club, get updates and see podcast recordings: https://rwd-rwe.club Disclaimer: The views expressed in this podcast are the guest's and host's alone, and do not reflect the official position of any organization or entity with whom they are, or have been, professionally affiliated.

Ep 225 [29 July 2026]: Sarah Daugherty PhD MPH (Principal Scientist at @Carelon) and Daniel Beachler PhD MHS (VP of Safety & Epidemiology at @Carelon) – We discussed their unique background and personal experiences, which led to a great discussion on what makes real-world evidence more meaningful? Beyond the Myths: The Value of Patient-Centered Research. We will discuss how incorporating patient preferences, experiences, and needs can strengthen evidence generation and help ensure research focuses on what matters most to patients. Please read Daniel's LinkedIn post: https://www.linkedin.com/feed/update/urn:li:activity:7414688910959611904/ Please check-out our website to join the club, get updates and see podcast recordings: https://rwd-rwe.club Disclaimer: The views expressed in this podcast are the guest's and host's alone, and do not reflect the official position of any organization or entity with whom they are, or have been, professionally affiliated.

Ep 206 [09 September 2026]: Michael Litten, Partner at Klein Hersh leading their Pharma & Technology recruiting practice – We discussed Michael's unique background and discussed the current hiring environment in the life science ecosystem, as well as search--with tips for candidates as they are approaching new career opportunities and for companies in need of their next (non-agentic) human hire. Please check-out our website to join the club, get updates and see podcast recordings: https://rwd-rwe.club Disclaimer: The views expressed in this podcast are the guest's and host's alone, and do not reflect the official position of any organization or entity with whom they are, or have been, professionally affiliated.